Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › WA › Seattle › NPI 1073599478
Lab

Laboratory Corporation of America

Laboratory Corporation of America was paid $186.69M by Medicaid between Jan 2018 and Dec 2024, across 449 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 7.2% of everything it billed.

33Billing provider infoLABORATORY CORPORATION OF AMERICA
SEATTLE, WA 98122
33aNPI1073599478assigned 12/16/2005
33bProvider typeClinical Medical Laboratory
28Total paid$186.69M
24GClaims17,061,269
24DCodes billed449
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Clinical Medical Laboratory providers in Washington

Rank by total paid#1 of 76
Median peer was paid$90K
This provider vs. median2,064×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official WILLIAMS, KIMBERLY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$2.0M$4.0M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
20182,063,155$22.84M
20192,303,868$24.44M
20202,102,135$24.12M
20212,598,973$32.39M
20222,667,794$29.34M
20232,761,412$27.37M
2024incomplete2,563,932$26.19M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 7.2% 188,977 168,426 $13.40M
80050 General health panel 6.1% 434,731 418,859 $11.44M
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 5.0% 353,274 330,059 $9.39M
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 5.0% 352,996 329,885 $9.28M
80061 Lipid panel 4.2% 923,511 887,084 $7.91M
80053 Comprehensive metabolic panel 3.7% 996,117 934,391 $6.83M
81420 Fetal chromosomal aneuploidy genomic sequence analysis panel 3.6% 18,024 17,807 $6.72M
84443 Thyroid stimulating hormone (TSH) 3.3% 564,936 541,717 $6.25M
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 3.2% 356,441 340,152 $5.90M
85025 Blood count; complete (CBC), automated, and automated differential WBC count 2.4% 864,527 799,109 $4.45M
83036 Hemoglobin; glycosylated (A1C) 2.4% 753,037 724,303 $4.40M
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types 1.9% 137,653 133,253 $3.50M
437 more codes
36415 Collection of venous blood by venipuncture 1.8% 1,581,701 $3.37M
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 1.8% 281,212 $3.37M
86803 1.7% 340,545 $3.22M
86480 1.6% 76,931 $2.99M
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer 1.5% 135,808 $2.86M
87086 Culture, bacterial; quantitative colony count, urine 1.3% 426,545 $2.49M
88305 Level IV - Surgical pathology, gross and microscopic examination 1.2% 41,464 $2.33M
82728 1.1% 234,780 $2.13M
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 1.1% 47,521 $2.06M
80081 1.1% 36,550 $2.02M
84439 1.0% 312,581 $1.92M
84403 1.0% 107,291 $1.89M
83013 <1% 35,998 $1.73M
82607 <1% 167,930 $1.70M
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed <1% 23,821 $1.45M
87507 <1% 4,524 $1.24M
82670 <1% 58,626 $1.16M
87340 <1% 174,398 $1.15M
81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants <1% 3,801 $1.13M
83550 <1% 182,799 $1.07M
82746 <1% 107,695 $1.06M
88142 <1% 61,146 $1.04M
80074 <1% 34,353 $1.02M
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 <1% 100,921 $982K
80048 Basic metabolic panel (calcium, ionized) <1% 180,685 $973K
85027 <1% 211,581 $902K
87902 <1% 5,159 $891K
86780 <1% 102,094 $891K
82274 <1% 79,418 $888K
83970 <1% 32,730 $887K
87186 <1% 135,514 $882K
84702 <1% 81,101 $854K
83540 <1% 195,551 $839K
80055 <1% 21,448 $835K
84153 <1% 74,276 $832K
87081 <1% 160,442 $825K
87522 Neg quan hep c or qual rna <1% 29,033 $818K
83880 <1% 35,171 $794K
86235 <1% 12,328 $789K
84402 <1% 45,269 $787K
86003 <1% 11,015 $779K
82570 <1% 222,622 $776K
87088 <1% 131,122 $735K
83001 <1% 55,131 $732K
84146 <1% 51,728 $728K
87480 <1% 50,045 $725K
84481 <1% 62,315 $717K
87660 <1% 50,037 $712K
86704 <1% 89,548 $698K
87510 <1% 50,040 $697K
82043 <1% 180,555 $695K
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe <1% 30,255 $687K
86706 <1% 95,389 $667K
87536 <1% 10,913 $663K
87077 <1% 108,104 $621K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets <1% 2,271 $566K
86762 <1% 63,105 $562K
88342 <1% 8,650 $527K
86140 <1% 143,780 $525K
87070 <1% 79,538 $518K
83002 <1% 37,173 $490K
88141 <1% 32,836 $489K
86592 <1% 166,491 $483K
86708 <1% 58,986 $475K
86038 <1% 55,947 $475K
86787 <1% 43,388 $419K
84144 <1% 27,483 $403K
86376 <1% 38,556 $400K
86696 <1% 26,306 $375K
81001 <1% 166,741 $358K
82784 <1% 34,218 $344K
83516 <1% 20,122 $342K
86850 <1% 60,783 $334K
82950 <1% 90,538 $330K
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 15,296 $325K
84480 <1% 31,952 $318K
80076 <1% 53,364 $305K
82627 <1% 19,039 $300K
83735 <1% 64,012 $284K
83655 <1% 30,199 $263K
83690 <1% 52,978 $261K
86769 <1% 8,465 $257K
85652 <1% 136,154 $255K
86665 <1% 10,480 $255K
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms <1% 5,747 $250K
86800 <1% 21,329 $241K
86200 <1% 25,811 $236K
82951 <1% 23,859 $233K
86695 <1% 23,899 $226K
88312 <1% 4,048 $220K
86360 <1% 6,622 $220K
82533 <1% 17,671 $208K
86160 <1% 13,596 $205K
86317 <1% 20,632 $204K
86431 <1% 48,685 $201K
84550 <1% 67,598 $200K
82105 <1% 17,514 $199K
87075 <1% 28,581 $197K
88341 <1% 2,508 $192K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed <1% 3,029 $185K
85610 <1% 67,585 $182K
87517 <1% 5,920 $177K
87150 <1% 23,146 $166K
87209 <1% 12,517 $166K
87427 <1% 19,673 $165K
84450 <1% 51,146 $164K
84436 <1% 35,498 $163K
84460 <1% 47,906 $163K
82565 <1% 51,507 $162K
86141 <1% 17,447 $154K
84445 <1% 4,058 $153K
86147 <1% 3,525 $153K
86765 <1% 17,423 $153K
83721 <1% 34,253 $148K
86364 <1% 11,305 $145K
82024 <1% 5,108 $140K
86709 <1% 18,190 $139K
87046 <1% 20,130 $137K
82247 <1% 47,981 $137K
86735 <1% 15,265 $134K
87045 <1% 19,629 $132K
86361 <1% 7,308 $130K
80164 <1% 16,602 $130K
84156 <1% 49,135 $126K
82248 <1% 40,360 $125K
83525 <1% 14,893 $122K
86870 <1% 3,658 $120K
86677 <1% 6,910 $120K
82977 <1% 27,736 $118K
85060 <1% 10,161 $117K
84100 <1% 39,017 $115K
86258 <1% 6,569 $115K
84270 <1% 7,273 $110K
86225 <1% 12,378 $109K
87255 <1% 4,130 $108K
82150 <1% 22,673 $107K
87625 <1% 4,694 $106K
81329 <1% 1,627 $104K
84681 <1% 7,077 $103K
80069 <1% 19,549 $102K
84165 <1% 14,224 $100K
82239 <1% 7,703 $99K
86900 <1% 53,548 $99K
87493 <1% 4,003 $98K
86901 <1% 53,613 $98K
80178 <1% 22,778 $96K
82550 <1% 21,065 $95K
82947 <1% 36,784 $94K
86664 <1% 8,272 $93K
83498 <1% 4,653 $92K
83090 <1% 8,227 $89K
85730 <1% 23,689 $88K
84703 <1% 16,587 $88K
82378 <1% 6,518 $86K
84154 <1% 7,624 $85K
87210 <1% 23,313 $85K
84520 <1% 34,322 $85K
87177 <1% 12,600 $82K
82652 <1% 5,357 $81K
82785 <1% 6,753 $78K
83615 <1% 21,333 $78K
82040 <1% 27,852 $78K
84425 <1% 5,402 $77K
84075 <1% 26,663 $76K
84479 <1% 17,418 $75K
86304 <1% 5,309 $74K
82672 <1% 5,021 $74K
86705 <1% 8,988 $72K
86334 <1% 5,094 $72K
81596 <1% 1,932 $71K
87205 <1% 22,195 $71K
82310 <1% 24,766 $69K
84155 <1% 30,147 $66K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed <1% 898 $66K
88304 <1% 2,864 $65K
83921 <1% 5,293 $65K
88307 <1% 400 $64K
83520 <1% 5,995 $64K
84466 <1% 7,372 $63K
88185 <1% 213 $63K
86300 <1% 3,651 $62K
80197 <1% 7,209 $61K
82330 <1% 6,558 $59K
86341 <1% 2,809 $58K
82679 <1% 3,371 $58K
82140 <1% 6,016 $58K
84482 <1% 5,024 $57K
86146 <1% 1,311 $57K
87324 <1% 6,523 $55K
83993 <1% 3,905 $55K
82952 <1% 18,083 $54K
87338 <1% 5,486 $53K
85379 <1% 7,233 $51K
84305 <1% 3,245 $51K
82390 <1% 6,624 $49K
84295 <1% 19,156 $49K
86663 <1% 5,006 $49K
82103 <1% 4,956 $47K
82435 <1% 18,771 $47K
87535 <1% 2,114 $46K
82088 <1% 1,565 $46K
87521 Neg quan hep c or qual rna <1% 1,740 $45K
85045 <1% 16,612 $45K
83521 <1% 1,736 $44K
84134 <1% 4,229 $43K
87529 <1% 1,662 $43K
80051 <1% 9,131 $43K
87350 <1% 5,226 $42K
84630 <1% 5,432 $42K
87329 <1% 4,706 $42K
82626 <1% 2,300 $42K
87486 <1% 1,666 $41K
87581 <1% 1,657 $41K
88230 <1% 490 $40K
36416 <1% 22,774 $40K
86357 <1% 1,665 $39K
86645 <1% 3,164 $39K
86644 <1% 3,781 $39K
86702 <1% 4,485 $38K
87184 <1% 7,139 $38K
84132 <1% 14,206 $38K
83021 <1% 2,792 $38K
82172 <1% 3,088 $37K
84207 <1% 2,026 $37K
88313 <1% 876 $36K
82525 <1% 4,322 $36K
81025 <1% 7,335 $36K
G0306 Complete cbc, automated (hgb, hct, rbc, wbc, without platelet count) and automated wbc differential count <1% 6,847 $35K
88112 <1% 1,149 $34K
88262 <1% 442 $34K
82397 <1% 3,363 $34K
86301 <1% 2,484 $34K
86593 <1% 10,967 $33K
85014 <1% 18,256 $31K
81003 <1% 21,460 $31K
85018 <1% 17,379 $29K
86682 <1% 2,961 $29K
86707 <1% 3,465 $29K
84478 <1% 8,120 $29K
85246 <1% 1,630 $28K
85245 <1% 1,588 $27K
84166 <1% 2,267 $27K
86256 <1% 2,341 $27K
86381 <1% 1,434 $27K
86618 <1% 1,567 $27K
86359 <1% 1,003 $25K
87641 <1% 949 $25K
84432 <1% 2,168 $25K
87563 <1% 1,370 $25K
80177 <1% 2,839 $25K
86308 <1% 6,380 $25K
87040 <1% 2,711 $24K
80175 <1% 2,758 $24K
84484 <1% 3,114 $24K
80156 <1% 2,822 $24K
85240 <1% 1,762 $24K
81374 <1% 4,818 $23K
86777 <1% 2,225 $23K
84244 <1% 1,451 $23K
83020 <1% 2,409 $23K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 1,090 $23K
86701 <1% 4,089 $23K
83010 <1% 2,499 $22K
G0145 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision <1% 3,595 $22K
87101 <1% 3,808 $22K
G0307 Complete (cbc), automated (hgb, hct, rbc, wbc; without platelet count) <1% 5,001 $22K
82787 <1% 1,191 $22K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 471 $21K
83883 <1% 2,331 $21K
83014 <1% 3,800 $21K
82374 <1% 8,044 $21K
82166 <1% 548 $20K
80185 <1% 2,499 $20K
82677 <1% 1,134 $20K
80159 <1% 1,915 $20K
G0472 Hepatitis c antibody screening, for individual at high risk and other covered indication(s) <1% 5,758 $19K
82653 <1% 994 $19K
86694 <1% 1,794 $18K
86356 <1% 1,200 $18K
84590 <1% 2,319 $18K
82465 <1% 7,259 $18K
87076 <1% 3,071 $17K
85007 <1% 7,308 $17K
84080 <1% 1,704 $17K
82553 <1% 2,107 $17K
86778 <1% 1,548 $17K
87538 <1% 655 $16K
86015 <1% 1,733 $16K
86037 <1% 699 $16K
81241 <1% 531 $15K
80299 <1% 868 $14K
86162 <1% 1,007 $14K
85660 <1% 3,389 $14K
87206 <1% 3,474 $14K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 1,467 $13K
86336 <1% 1,084 $12K
83718 <1% 2,303 $12K
86060 <1% 2,292 $12K
81015 <1% 5,829 $12K
82157 <1% 546 $12K
86255 <1% 1,339 $12K
G0328 Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous <1% 4,682 $12K
85049 <1% 4,741 $11K
84446 <1% 1,146 $11K
83789 <1% 713 $11K
86008 <1% 466 $11K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed <1% 116 $11K
0202U Oncology (prostate), multianalyte, gene expression profiling <1% 420 $11K
82985 <1% 1,165 $11K
0352U <1% 73 $9K
86337 <1% 586 $9K
82340 <1% 2,098 $9K
81256 <1% 291 $9K
82705 <1% 2,353 $9K
85613 <1% 1,129 $8K
83935 <1% 1,810 $8K
87254 <1% 561 $8K
86738 <1% 444 $8K
83695 <1% 1,133 $8K
82085 <1% 1,152 $8K
82668 <1% 632 $8K
86231 <1% 714 $8K
86036 <1% 779 $8K
85384 <1% 1,224 $7K
0097U <1% 157 $7K
88189 <1% 182 $7K
82164 <1% 682 $7K
80162 <1% 894 $7K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV <1% 70 $7K
89055 <1% 2,034 $7K
82731 <1% 120 $6K
88184 <1% 213 $6K
83631 <1% 464 $6K
84410 <1% 182 $6K
82955 <1% 820 $6K
87328 <1% 689 $6K
86880 <1% 1,649 $6K
87799 <1% 369 $6K
84300 <1% 1,641 $5K
83930 <1% 1,213 $5K
84145 <1% 319 $5K
87900 <1% 52 $5K
99199 Unlisted special service, procedure or report <1% 3,103 $5K
82104 <1% 472 $5K
86658 <1% 199 $4K
80305 <1% 583 $4K
G0103 Prostate cancer screening; prostate specific antigen test (psa) <1% 3,400 $4K
80183 <1% 454 $4K
86617 <1% 177 $4K
81401 <1% 71 $4K
80202 <1% 434 $4K
85048 <1% 2,151 $4K
80165 <1% 1,318 $4K
86671 <1% 376 $4K
0099U <1% 90 $4K
87481 <1% 199 $3K
82747 <1% 300 $3K
85004 <1% 754 $3K
82552 <1% 359 $3K
87106 <1% 429 $3K
87230 <1% 217 $3K
86355 <1% 129 $3K
82610 <1% 256 $3K
87420 <1% 342 $3K
G0475 Hiv antigen/antibody, combination assay, screening <1% 3,174 $3K
84255 <1% 163 $3K
89060 <1% 552 $3K
87207 <1% 629 $3K
89051 <1% 669 $3K
83835 <1% 215 $3K
87807 <1% 272 $3K
82681 <1% 126 $2K
85598 <1% 679 $2K
85041 <1% 985 $2K
82575 <1% 262 $2K
85670 <1% 510 $2K
82656 <1% 222 $2K
80184 <1% 188 $2K
84140 <1% 140 $2K
84163 <1% 157 $2K
86804 <1% 160 $2K
81291 <1% 225 $1K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets <1% 23 $1K
83704 <1% 80 $1K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 43 $1K
87252 <1% 59 $1K
87497 <1% 41 $1K
83986 <1% 469 $1K
G0124 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician <1% 231 $1K
83825 <1% 90 $1K
82542 <1% 70 $1K
84378 <1% 107 $976.25
87116 <1% 127 $908.16
G0123 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision <1% 892 $885.19
81243 <1% 52 $842.73
86747 <1% 37 $822.98
83088 <1% 42 $781.82
81240 <1% 26 $610.08
86335 <1% 30 $557.46
84597 <1% 56 $507.14
85306 <1% 40 $472.25
80158 <1% 30 $428.85
80203 <1% 44 $426.32
81479 Unlisted molecular pathology procedure <1% 25 $416.74
83625 <1% 55 $410.21
82642 <1% 58 $403.83
84133 <1% 127 $369.94
87015 <1% 71 $326.57
S3600 Stat laboratory request (situations other than s3601) <1% 5,751 $252.90
85385 <1% 27 $227.14
82436 <1% 64 $225.84
85303 <1% 26 $212.09
87172 <1% 60 $201.90
81002 <1% 91 $191.94
84181 <1% 13 $180.78
82175 <1% 14 $179.84
82232 <1% 12 $168.69
83003 <1% 14 $156.79
87109 <1% 12 $144.35
83519 <1% 15 $136.17
86340 <1% 13 $135.68
86790 <1% 13 $124.30
80186 <1% 14 $115.82
80235 <1% 13 $110.24
87899 <1% 14 $107.79
86606 <1% 12 $107.61
82180 <1% 13 $78.96
85300 <1% 13 $77.38
P9604 Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge <1% 606 $59.11
P9603 Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled <1% 510 $50.90
83874 <1% 12 $43.86
87220 <1% 15 $32.89
99213 Doctor's office visit, returning patient (routine) 0% 16 $0.00
81377 0% 42 $0.00
80356 0% 150 $0.00
80365 0% 152 $0.00
80361 0% 156 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialWILLIAMS, KIMBERLY (VP)
Same official

Other billing entities under WILLIAMS, KIMBERLY

Full network →
ProviderLocationPaid
Laboratory Corporation of America HoldingsBurlington, NC$1.44B
Laboratory Corporation of America HoldingsRaritan, NJ$717.47M
Laboratory Corporation of America HoldingsDublin, OH$617.02M
Laboratory Corporation of America HoldingsBirmingham, AL$289.12M
Laboratory Corporation of AmericaPhoenix, AZ$265.90M
Laboratory Corporation of America HoldingsBurlington, NC$264.26M
Laboratory Corporation of America HoldingsCharleston, WV$220.04M
Laboratory Corporation of AmericaTampa, FL$171.13M
Laboratory Corporation of AmericaSan Diego, CA$147.14M
Laboratory Corporation of AmericaHouston, TX$103.81M
Laboratory Corporation of AmericaEnglewood, CO$77.80M
Laboratory Corporation of AmericaDallas, TX$77.42M
Laboratory Corporation of AmericaBurlington, NC$59.75M
Medtox Laboratories, INCSaint Paul, MN$47.72M
Laboratory Corporation of America HoldingsBurlington, NC$15.65M
Laboratory Corporation of AmericaSan Antonio, TX$11.67M
Tri-Cities Laboratory, LLCKennewick, WA$8.69M
Laboratory Corporation of America HoldingsMonroe, LA$3.39M
Laboratory Corporation of AmericaItasca, IL$3.37M
Laboratory Corporation of AmericaAlbany, NY$2.06M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.